Skip to main content

Market Overview

FDA Approvals And Changes For The Week Ending February 14, 2014


The week ending February 14 was a nightmare for the Food and Drug Administration, as numerous companies sought not only manufacturing changes, but drug approvals as well. Below are some of the more notable changes and approvals.

February 13:

Some companies that sought after manufacturing changes include: Amylin (NASDAQ: AMLN) with its Byetta, which is an injectabe drug. Pfizer (NYSE: PFE) with its Children's Advil, which is a tablet and Amarin Pharmaceuticals (NASDAQ: AMRN) with its Vascepa, which is a capsule.

Sun Pharma Global had its drug Temozolomide approved. The company is based outside of the United States and and had its consolidated net profit increase by 74 percent.

February 12:

Pharmacyclics (NASDAQ: PCYC) sought drug approval with its Imbruvica. The drug is meant to help patients who have leukemia. The stock traded at $133.28 before this week's open, after having been down $5.58 or four percent.

February 11:

Innopharma Licensing had its drug Acetylcysteine approved.

Macleods Pharms had its drug Rizatriptan Benozate approved; it is currently not trading publicly on any stock exchange.

ACIC Fine Chemicals had its drug Tranexamic Acid approved.

February 10:

Akorn (NASDAQ: AKRX) had its drug Ketorolac Tromethamine approved; the stock is was trading at $24.00 at week's open and has a PE of 60.


Related Articles (PCYC)

View Comments and Join the Discussion!

Posted-In: News FDA

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at